Variable | Coefficient (SE) | 95% Confidence interval | P-value |
---|---|---|---|
Log alanine amino transferase longitudinal sub-model | |||
 Maternal age | 0.0006 (0.0023) | − 0.00394, 0.0052 | 0.793 |
 Treatment | |||
  ASAQ | − 0.0036 (0.0275) | −0.0575, 0.0504 | 0.897 |
  DHAPQ | 0.0031 (0.0275) | −0.0508, 0.0570 | 0.909 |
 Second trimester | −0.0212 (0.0311) | − 0.0820, 0.0397 | 0.496 |
 Constant | 2.8221 (0.0609) | 2.7027, 2.9415 | < 0.001 |
Log total bilirubin longitudinal sub-model | |||
 Maternal age | −0.0026 (0.0035) | −0.0095, 0.0043 | 0.464 |
 Treatment | |||
  ASAQ | −0.0229 (0.0424) | −0.1059, 0.0601 | 0.589 |
  DHAPQ | −0.0413 (0.0422) | −0.1240, 0.0414 | 0.328 |
 Second trimester | −0.1786 (0.0493) | −0.2752, − 0.0820 | < 0.001 |
 Constant | 2.3103 (0.0963) | 2.1216, 2.4990 | < 0.001 |
Concomitant medication count sub-model | |||
 Maternal age | 0.0086 (0.0052) | −0.0017, 0.0189 | 0.101 |
 Treatment | |||
  ASAQ | −0.1841 (0.0619) | −0.3054, − 0.0629 | 0.003 |
  DHAPQ | −0.1723 (0.0610) | − 0.2918, − 0.0528 | 0.005 |
 Second trimester | 0.2861 (0.0718) | 0.1454, 0.4268 | < 0.001 |
 Constant | 0.9147 (0.1395) | 0.6414, 1.188 | < 0.001 |
Adverse events count sub-model | |||
 Maternal age | 0.0189 (0.0088) | 0.0017, 0.0362 | 0.031 |
 Treatment | |||
  ASAQ | 0.2118 (0.1039) | 0.0082, 0.4154 | 0.041 |
  DHAPQ | −0.0508 (0.1046) | −0.2559, 0.1542 | 0.627 |
 Second trimester | 0.3986 (0.1222) | 0.1592, 0.6381 | 0.001 |
  αlog(ALT) | − 0.0288 (0.2427) | − 0.5045, 0.4469 | 0.906 |
  αlog(bilirubin) | 0.1153 (0.1042) | − 0.0889, 0.3194 | 0.269 |
  αconcmed | 1.7487 (0.1029) | 1.5471, 1.9503 | < 0.001 |
  Constant | −0.8220 (0.7739) | −2.3388, 0.6949 | 0.288 |
Patient-specific random effects standard deviations | |||
 Standard deviations | |||
  δlog(ALT) | 0.2547 (0.0119) | 0.2324, 0.2792 |  |
  δlog(bilirubin) | 0.5025 (0.0154) | 0.4732, 0.5336 |  |
  δlog(concmed) | 0.5378 (0.0248) | 0.4914, 0.5887 |  |